Natera (NASDAQ:NTRA) & Ramsay Health Care (OTCMKTS:RMYHY) Head to Head Review

Ramsay Health Care (OTCMKTS:RMYHY) and Natera (NASDAQ:NTRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability.

Institutional and Insider Ownership

99.9% of Natera shares are held by institutional investors. 5.6% of Natera shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Ramsay Health Care has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ramsay Health Care and Natera, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ramsay Health Care	0	2	0	0	2.00
Natera	2	3	16	1	2.73

Natera has a consensus target price of $194.89, indicating a potential downside of 0.79%. Given Natera’s stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Ramsay Health Care.

Profitability

This table compares Ramsay Health Care and Natera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ramsay Health Care	N/A	N/A	N/A
Natera	-12.89%	-22.22%	-15.03%

Earnings and Valuation

This table compares Ramsay Health Care and Natera”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ramsay Health Care	N/A	N/A	N/A	N/A	N/A
Natera	$1.70 billion	15.89	-$190.43 million	($1.91)	-102.85

Ramsay Health Care has higher earnings, but lower revenue than Natera.

Summary

Natera beats Ramsay Health Care on 8 of the 11 factors compared between the two stocks.

About Ramsay Health Care

Ramsay Health Care Limited owns and operates hospitals. The company offers health care services to public and private patients. It operates facilities in approximately 530 locations in the Asia Pacific, the United Kingdom, France, and Nordics. Ramsay Health Care Limited was founded in 1964 and is based in Sydney, Australia.

About Natera

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.